FDA v. Alliance for Hippocratic Medicine

Whether respondents have Article III standing to challenge FDA's 2016 and 2021 regulatory actions regarding mifepristone.

The Court unanimously held that the plaintiffs lacked standing to challenge FDA actions expanding access to the abortion drug mifepristone. The doctors and organizations failed to show they suffered concrete injury from the FDA's decisions.